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ABSTRACT
Objective: To assess the value of monitoring response to
bisphosphonate treatment by means of measuring bone
mineral density.
Design Secondary analysis of trial data using mixed
models.
Data source The Fracture Intervention Trial, a randomised
controlled trial that compared the effects of alendronate
and placebo in 6459 postmenopausal women with low
bone mineral density recruited between May 1992 and
May 1993. Bone density measurements of hip and spine
were obtained at baseline and at one, two, and three
years after randomisation.
Main outcome measures Between-person (treatment
related) variation and within-person (measurement
related) variation in hip and spine bone mineral density.
Results The mean effect of three years’ treatment with
alendronate was to increase hip bone mineral density by
0.030 g/cm
2. There was some between-person variation
in the effects of alendronate, but this was small in size
compared with within-person variation. Alendronate
treatment is estimated to result in increases in hip bone
density ≥0.019 g/cm
2 in 97.5% of patients.
Conclusions: Monitoring bone mineral density in
postmenopausal women in the first three years after
starting treatment with a potent bisphosphonate is
unnecessary and may be misleading. Routine monitoring
should be avoided in this early period after
bisphosphonate treatment is commenced.
INTRODUCTION
Osteoporosis and associated fragility fractures are
major threats to the health of ageing populations
worldwide.
1 Evidence based clinical guidelines pro-
vide advice on how to identify and treat individuals at
high risk of fracture.
2-6 Bisphosphonates in particular
are important for preventive treatment. What is less
certain is how to determine an individual’s true
response once treatment is started.
Guidelines for treatment of postmenopausal osteo-
porosisdifferintheirrecommendationsformonitoring
after starting bisphosphonates. The US National
Osteoporosis Foundation and the American Associa-
tion of Clinical Endocrinologists recommend routine
monitoringofbonemineraldensitywithintwoyearsof
starting treatment.
23 The UK National Osteoporosis
Guidelines Group, US National Institutes of Health,
and the Osteoporosis Society of Canada do not make
a recommendation either way on monitoring.
457The
UK guidelines recommend that further research is
needed and the North American guidelines recom-
mendthattreatmentshouldnotbestoppedorchanged
because of a modest observed loss in density.
Bone density monitoring of patients receiving treat-
ment consumes considerable health resources. The
availability of bone densitometry varies substantially
between countries, with about 10 times as many den-
sitometers per million population in the US as in the
UK(35.8v3.7scanners/millionpopulation).Although
thisreflectsuseofdensitometryforcasefindingaswell
asformonitoringtreatment,it islikelythatoverhalfof
all measurements done are for monitoring.
8
Meta-analyses oftrials ofanti-resorptive agentssuch
as bisphosphonates have found significant association
betweentreatmenteffectsonbonemineraldensityand
fracture risk,
9-11 with the relation seeming to be stron-
ger for non-vertebral factures
11 than vertebral
fractures.
910 Although this suggests that bone density
may be considered as an intermediate outcome for
monitoring treatment effects at a population level,
moreevidenceisneededbeforewecandecidewhether
itshouldbeusedformonitoringtreatmenteffectsatan
individual level.
Inthispaperweinvestigatetheeffectsofalendronate
on bone density at the individual level. We compare
the variability of bone density for patients receiving
placebo with that for patients taking treatment, using
mixed models
12 to make inferences about whether the
effect of treatment varies among individuals or is uni-
form.If the treatmenteffectdidnot vary betweenindi-
viduals we could infer that monitoring individuals’
response to treatment is unnecessary as the effect of
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dicted before treatment is started. A finding that treat-
menteffectvariedbetweenindividualsmayimplythat
monitoringindividuals’responsetotreatmentisneces-
saryifthevariationisgreatenoughtobeclinicallyrele-
vant. This would occur if a substantial proportion of
patients failed to meet a treatment threshold—for
example, if the treatment effects ranged from no effect
(orevenreductioninbonedensity)uptoalargegainin
bonedensity(seeBelletal
13foramoredetaileddiscus-
sion on when variation in treatment effects is likely to
be clinically relevant). We used data from a large ran-
domised trial to determine whether routine monitor-
ing of bone mineral density is warranted after starting
alendronate treatment.
METHODS
Study design and population
WeanalyseddatafromtheFractureInterventionTrial
(FIT), a randomised trial that compared the effects of
alendronate with placebo in 6459 postmenopausal
women with low bone mineral density (≤0.68 g/cm
2 at
baseline).
14 The trial had two arms—the vertebral frac-
ture arm, which included 2027 women who had ver-
tebral fractures identified on radiographs at baseline,
15
and the clinical fracture arm, which included 4432
women without baseline vertebral fractures.
16 Patients
for both arms were recruited between May 1992 and
May 1993. Data from both arms are included in this
paper, with an adjustment made for the arm a particu-
lar patient was in by including a term to represent trial
arm in the models. Analysis was by intention to treat,
and all subjects were included regardless of compli-
ance with study treatment or fracture outcomes.
Patients were randomly allocated to daily alendro-
nate or placebo. Alendronate dose was initially 5 mg/
dayfortwoyearsbutwasincreasedto10mg/dayatthe
second annual visit because other trials suggested that
10mg/dayhadgreatereffectsonbonemineraldensity.
Women in each treatment group who had dietary cal-
cium intakes <1000 mg/day at baseline (82% of parti-
cipants) were asked to take a daily supplement
containing 500 mg of elemental calcium and 250 IU
of vitamin D.
Monitoring measurements
Bonemineraldensitywasmeasuredatthehipandpos-
terior-anterior(PA)spineonallparticipantswithHolo-
gic QDR 2000 densitometers at baseline and at yearly
intervals after randomisation. Serial measurements
were madewiththe samemachineateachclinical cen-
tre. Quality control measures have been described
previously.
14 We used bone mineral density data
frombaselineandthefirstthreeyearsafterrandomisa-
tion to evaluate response to treatment.
Statistical analysis
Mixed models are a powerful method for analysing
data from longitudinal studies, in which there are mul-
tiplemeasurementsoneachsubject.
1718Thisapproach
allows explicit modelling of the within-person and
between-personvariationintheoutcome,whiletaking
into account the correlation between measurements
taken on the same individual. In this type of analysis,
predictive factors may be fitted to have the same effect
for everyone, in which case they are said to be fixed
effects (these effects are equivalent to the estimated
effects in ordinary least squares regression models).
Alternatively, the predictive factors may be fitted to
have effects that differ between individuals, in which
case they are said to have random effects (these effects
arenotallowedforinordinaryleastsquaresregression
models). These alternative models can be compared
using likelihood ratio tests to determine which model
providesthebestfitforthedata.Ifthereisnovariation
in the treatment effectbetweenpatientsthenwe would
expect the mixed models to find that treatment has a
fixedeffectandnorandomeffects.Conversely,ifthere
is variation in the treatment effects between patients
then we would expect the mixed models to find that
treatment has random effects.
We fitted a series of mixed models using bone
mineral density measurements over three years. We
used the likelihood ratio test to compare models
where treatment effect was the same for everyone
(treatment had a fixed effect) with models where treat-
ment effect differed between individuals (treatment
had random effects). (For a more detailed explanation
ofmodelfitting,seeappendix1onbmj.comandBellet
al
12).
Forfixedeffectsweestimatedthemeaneffectapplic-
able to all patients, whereas for random effects we esti-
mated the mean and standard deviation of effects
across patients. For random effects we also estimated
a 95% distribution of treatment effects, an interval in
whichthetreatmenteffectfor95%ofthestudypopula-
tionshouldlie(meanvalue+/−(1.96×standarddevia-
tion)).
As the primary analysis we used hip bone mineral
density measurements alone (or univariate response
models). The hip is the best site for predicting risk of
hip fracture and osteoporotic fractures overall.
19 How-
ever many clinicians use both hip and spine bone den-
sity measurements to monitor treatment effects. Hip
and spine bone mineral density measurements made
at the same time on the same individual are
correlated.
20 As an extension to the analysis outlined
above, we also fitted models that considered both hip
and spine bone mineral density simultaneously, while
allowing for their correlation (or bivariate response
models).
Analysis was done using MLwiN software package
(Centre for Multilevel Modelling, University of Bris-
tol) with models fitted using iterative generalised least
squares.
RESULTS
The results of the primary mixed models analysis
(where hip bone mineral density was the outcome)
are shown in figures 1 and 2 (the full statistical results
are presented in appendix 2 on bmj.com). Fig 1 shows
the mean bone mineral density trajectories for
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after starting treatment. These represent the mean
effects (based on both the fixed and random effects)
found in the final mixed model. The mean effect of
time in the placebo group was a decrease of 0.004 g/
cm
2peryear(P<0.001),shownbythedownwardslope
for the placebo mean trajectory in fig 1. The mean
effect of one year’s treatment with alendronate (rela-
tive to placebo) was an increase of 0.013 g/cm
2
(P<0.001), which is shown in fig 1 by the difference in
the mean trajectories for alendronate and placebo at
year 1 (the intercept). The mean effect of time in the
alendronate group (relative to the placebo group) was
an increase in bone mineral density of 0.0085 g/cm
2
peryear(P<0.001),shownbythedivergingtrajectories
(difference in slopes) of the two treatment groups in
fig 1. There was no evidence that treatment effect was
modified by baseline bone density (P=0.65), age
(P=0.65), body mass index (P=1.0), general health
(P=0.11), or trial arm (P=0.32).
Fig 2 shows the variance between individuals at the
three time points and represents the variances of the
random effects of the final mixed model (excluding
residual variances). We first consider the placebo var-
iance trajectory. There was considerable variation
between patients in the placebo group at one year
(P<0.001), which is shown in fig 2 by the variance of
theplacebogroupatyear1.Inaddition,therewasvar-
iation between individuals in how their bone mineral
density changed over time (P<0.001), shown by the
increasing variance in both groups over the three
years.
Therewasalsoconsiderablewithin-personvariation
overtime(notshowninthefigures).Thewithin-person
variation was significantly lower (P<0.001) in the
group receiving alendronate (standard deviation
0.012 g/cm
2) compared with the placebo group (SD
0.014 g/cm
2). Bland-Altman plots
21 showed that
within-person variation did not depend on the indivi-
dual’s mean level of bone mineral density (data not
shown).
Afterallowingforthestatisticallysignificantrandom
effects of background sources of variation, there
remained strong evidence of variation between indivi-
duals in the effects of alendronate on hip bone mineral
density (P=0.008), shown in fig 2 by the difference in
thevariancetrajectoriesforalendronateandplaceboat
year 1. Although the variation in treatment effects was
statistically significant, it was small in size with a stan-
dard deviation of 0.006 g/cm
2, which is about half the
standard deviation of within-person variation on treat-
ment. A comparison of variances was even more
marked,withthevarianceofbetween-personvariation
intreatmenteffectsbeingonlyaboutonetenththevar-
ianceofbackgroundwithin-personvariation.The95%
distribution for the between-person effects of one
year’s treatment on hip bone density did not overlap
zero, ranging from an increase in hip bone mineral
density of 0.002 g/cm
2 (2.5th centile) to an increase of
0.024 g/cm
2 (97.5th centile).
Therewasnostrongevidenceofadditionalbetween-
person variation in treatment effects after one year
(P=0.07), shown in fig 2 by the parallel variance trajec-
tories of the two treatment groups. After three years,
the mean cumulative treatment effect was 0.030 g/cm
2
(0.013 g/cm
2 +( 2× 0.0085 g/cm
2)). The standard
deviation of between-person variation in cumulative
treatment effect was 0.006 g/cm
2, the same as the var-
iation in treatment effect after one year. The 95% dis-
tribution for the effects of three years’ treatment
ranged from an increase in bone mineral density of
0.019 g/cm
2 (2.5th centile) to an increase of 0.041 g/
cm
2 (97.5th centile).
The bivariate response analysis (whereboth hipand
spine bone mineral density were considered together)
yielded similar conclusions to the univariate response
analysispresentedabove.Wefoundstrongevidenceof
between-person variation in the effects of treatment
(P<0.001), but again the absolute size of this variation
was small (standard deviation of between-person var-
iation in treatment effect was 0.006 g/cm
2 for hip and
0.007 g/cm
2 for spine). In the bivariate response ana-
lysis the 95% distributions for the effect of one and
three years’ treatment with alendronate on hip bone
mineral density were the same as the univariate analy-
sis. The 95% distribution for the effects of one year’s
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Fig 1 | Mean bone mineral density over time for 6459
postmenopausal women with low bone mineral density
treated with alendronate or placebo. (As this is a randomised
trial, at year 0 the mean bone mineral density is similar for the
alendronate and placebo groups)
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Fig 2 | Between-person variances in bone mineral density over
time for 6459 postmenopausal women with low bone mineral
density treated with alendronate or placebo. (As this is a
randomised trial, at year 0 the between-person variance is
similar for the alendronate and placebo groups)
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lap zero and ranged from an increase of 0.015 g/cm
2
(2.5th centile) to an increase of 0.042 g/cm
2 (97.5th
centile).At the endof threeyears,the 95%distribution
for the effects of treatment on spine bone mineral den-
sityrangedfromanincreaseof0.037g/cm
2(2.5thcen-
tile) to an increase of 0.064 g/cm
2 (97.5th centile). The
correlation between the effects of treatment on hip
bone mineral density and spine bone mineral density
over the three year time period for an individual was
0.90.
DISCUSSION
In this large placebo controlled trial of alendronate
treatment of postmenopausal women with low bone
density and with serial bone mineral density measure-
ments, we found that three years of treatment resulted
in an average increase in hip bone mineral density of
0.030 g/cm
2 against a background average decrease in
hip bone mineral density of 0.012 g/cm
2 with placebo.
We found small between-person differences in the
effects of alendronate on bone mineral density. These
differences were small compared with background
variation in bone mineral density measurements
within patients. Moreover, treatment seemed benefi-
cial for the vast majority of patients. Three years of
treatment with alendronate resulted in increases in
hip bone mineral density ≥0.019 g/cm
2 for 97.5% of
patients. Increases in bone density of at least this size
are likely to be considered sufficient to continue ther-
apyinmostclinicalpopulations.Thismeansthat,even
though we found the effects of alendronate to vary
between individuals, the size of this variation is not
clinically relevantand monitoring individualresponse
isnotneeded.Thehighcorrelationbetweentheeffects
of treatment on hip bone mineral density and spine
bone mineral density (r=0.90) confirms previous
findings
19 that there is minimal gain from taking mea-
surementattwositesratherthanone.Ourfindingssug-
gest that bone density monitoring is not warranted at
either hip or spine skeletal sites.
Thelargewithin-personvariationinbonedensitywe
foundinthisstudyislikelytobeabestcasescenario,as
bone density measurements made in clinical trials
probably have considerably less within-person varia-
tion than measurements made in clinical practice.
Within-person variation that is at least as large as that
wehaveestimatedindicatesthatanytruedifferencesin
treatment effects in a clinical setting are likely to be
hidden.Thisprovidesfurtherrationaletonotroutinely
monitorbonedensityresponsetooralbisphosphonate
treatment.
Clinicians may cite other reasons for monitoring
besides estimating the intended effects of treatment.
One common reason given is to assess adherence to
treatment.
2 However, the large background within-
person variation for bone mineral density means that
monitoring is unlikely to give reliable information
about whether the drugs were taken as prescribed.
Patient’sself reportson structured interview oftencor-
relate better with pill count (a reference standard for
adherence measures) than do intermediate outcomes
(suchasbloodpressuremeasurementofpatientstaking
antihypertensive drugs).
22 In addition, most problems
with adherence to osteoporosis treatments occur
within three months of starting treatment,
23 much ear-
lier than the first monitoring for response at one year,
providing further argument against routine bone den-
sity monitoring for enhancing adherence to treatment.
Non-adherence is best detected by direct interview
22
and best increased by making patients active partici-
pants in their treatment.
24
Other potent oral bisphosphonates such as risedro-
nate and ibandronate operate by a similar mechanism
toalendronate.
25Itisreasonable,therefore,togeneral-
ise our results on the effects of three years of alendro-
nate treatment to the effects of other potent oral
bisphosphonates of roughly equivalent dose in post-
menopausal women. Further work is needed to gener-
alise beyond this group of drugs—for example,
analyses of data from trials evaluating intravenous
bisphosphonates and non-bisphosphonates (such as
oestrogen, oestrogen agonist/antagonists, parathyroid
hormone,and strontiumranelate) are neededto deter-
mine the value of monitoring with these treatments.
Where data are available on individual patients,
mixed models can be used to estimate the variation in
treatment effects.
12 Where only summary data are
available, an alternative method may be used that has
more restrictive assumptions
13 (see appendix 3 on
bmj.com for an example of this method). Future trial-
istscoulddirectlyreportonthevariationbetweenpeo-
ple in treatment effects, in addition to the average
treatment effect that is often reported at present. In
this way not only would trialsinform clinical decisions
on which treatment to choose but also when response
monitoring may be helpful (when there is clinically
relevant variation between people in the treatment
effects).
Our findings support a recommendation against
routine monitoring in the first three years after potent
bisphosphonate therapy is started. Other work with
datafromtheFractureInterventionTrialalsosupports
not monitoring bone density in the first few years of
alendronate treatment. Women observed to have no
net change in bone mineral density after four years of
treatment were found to have a high probability of
responding to treatment.
26 Reductions in fracture risk
with alendronate treatment were shown for women
who were observed to lose bone density during
treatment.
27Failuretorecognisethismeasurementvar-
iation may lead clinicians to make inappropriate
changes to treatment or to delay taking action when
they should intervene.
2328
In summary, bone density increases sufficient to
continue therapy unaltered occurred in virtually all
osteoporotic women treated with a potent oral bispho-
sphonate for three years. Monitoring bone mineral
density in this early period after starting treatment is
unnecessary, and, because of the potential to mislead,
it is best avoided.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Many clinicians monitor bone mineral density to estimate a patient’sr e s p o n s et o
bisphosphonate therapy for osteoporosis, but there is no evidence that this practice is of
clinical benefit
Monitoring bone mineral density consumes considerable health resources
The observed response to bisphosphonate therapy may not reflect the true response
because of measurement variability
WHAT THIS STUDY ADDS
Between-person variation in the effects of alendronate on bone mineral density is small
compared to within-person variation and is not clinically relevant
Monitoring bone mineral density in postmenopausal women after starting a potent oral
bisphosphonate is unnecessary and, because of the potential to mislead, is best avoided
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